{'fraction_non_alphanumeric': 0.011614401858304297, 'fraction_numerical': 0.0, 'mean_word_length': 5.113475177304965, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Serum level of anti-neurotrophine antibodies and activity of proteolytic enzymes in patients with sensorineural loss of hearing].

The objective of this study was to determine the level of antibodies against nerve growth factor in the serum, activity of elastase in leukocytes and concentration of its inhibitor in patients with sensorineural loss of hearing of different severity, and degree of progression. It was shown that patients with the rapidly developing form of the disease have lower titers of antibodies against nerve growth factor compared with their normal values and an unfavourable ratio of activities of leukocytic elastase and its inhibitor. The patients were divided into three groups based on the level of antibodies against nerve growth factor. They were found to differ in terms of the state of the system of proteolytic enzymes in blood.